Ondas Q2 2026 Earnings Show Record Revenue, Wider Loss

Ondas Q2 2026 earnings reported record revenue and raised guidance, but investor focus on a wider adjusted loss and dilution kept pressure on shares.

August 13, 2026·2 min read
View all news articles
Flat vector satellite antenna straining under backlog to symbolize Ondas Q2 2026 earnings revenue versus dilution tension.

KEY TAKEAWAYS

  • Recorded Q2 revenue of $84M and raised full-year 2026 guidance to $525M-$550M.
  • Reported backlog roughly $613M and $757M pro forma including acquisitions.
  • Investors focused on an adjusted loss per share of $0.19, dilution, and very high short interest.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Ondas Holdings Inc. (ONDS) reported record Q2 2026 revenue and raised its full-year outlook on Aug. 13, 2026, but investor focus on an adjusted loss per share and dilution tied to recent acquisitions kept pressure on the shares.

Record Revenue, Backlog, and Raised Guidance

Ondas said in a press release that Q2 revenue reached $83.8 million, a 67% increase from the prior quarter and more than 13 times the $6.3 million reported in Q2 2025. The company secured $175 million in new orders during the quarter and an additional $105 million in orders through early Q3. This brought reported backlog to approximately $613 million as of June 30, 2026, rising to $757 million on a pro forma basis after including the DZYNE and Cyberhawk acquisitions, which closed in Q3.

The company raised its full-year 2026 revenue guidance to a range of $525 million to $550 million and said it was accelerating the timeline for adjusted EBITDA profitability. The expanded backlog and acquisitions broaden Ondas’s commercial runway and support the higher revenue target.

Wider Loss, Dilution, and High Short Interest

Investor concern centered on an adjusted loss per share of $0.19, wider than consensus estimates near a $0.10 loss. The company also reported an adjusted EBITDA loss of $50.6 million. Dilution from the DZYNE acquisition and very high short interest in ONDS shares added to market pressure.

Ondas’s larger order book and backlog clarify its revenue trajectory, but its commitment to accelerate adjusted EBITDA profitability will be key for investors weighing the impact of near-term losses and elevated short-interest headwinds.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

OpenAI Employee Arrested Over Hidden Recording Device

OpenAI Employee Arrested Over Hidden Recording Device

OpenAI employee arrested after a hidden device was discovered; company says models identified installer and found no data loss easing investor risk.

Cipher Digital Convertible Notes Proposal Sends Shares Lower

Cipher Digital Convertible Notes Proposal Sends Shares Lower

Cipher Digital convertible notes proposal would raise $850 million and include a concurrent exchange, raising dilution concerns and pressuring shares.

Character.AI Bankruptcy Draws Disney Interest

Character.AI Bankruptcy Draws Disney Interest

Character.AI bankruptcy starts a Section 363 sale with Disney as stalking-horse and $20 million bid, compressing the auction and shaping recoveries.

AST SpaceMobile Downgrade Sparks Concern

AST SpaceMobile Downgrade Sparks Concern

AST SpaceMobile downgrade after Piper Sandler cut its target, citing launch pace doubts and SpaceX competition, tightening trader positioning.

Six Flags Over Georgia Incident Prompts Ride Closures

Six Flags Over Georgia Incident Prompts Ride Closures

Six Flags Over Georgia incident triggered precautionary coaster closures and state reviews, raising near-term operational risk to attendance and shares.

Johnson & Johnson Q3 2026 Earnings Rise, MedTech Lags

Johnson & Johnson Q3 2026 Earnings Rise, MedTech Lags

Johnson & Johnson Q3 2026 earnings raised guidance to a $101.2 billion sales midpoint while MedTech weakness may force traders to reprice device risk.